“These companies are all making important strides in next-gen solutions for COVID-19, cancer and other sectors. But remember, they’re small companies in a risky space, nibble on them and be patient,” advise the authors of today’s article in regards to the seven “A-rated” aggressive biotech stocks they highlight. For these seven biotech stocks – and whether they could be “Master Key” investments – CLICK HERE.
The portfolio manager of one biotech-focused hedge fund recently invested a total of $60 million in three biotech stocks – and given his strong performance record and ability to beat the wider biotech sector with his picks, it may be worth taking a look at his selections. For the three biotech stocks in question, CLICK HERE.
While the author of today’s article acknowledges that “biotech investors…tend not to be a squeamish bunch”, he observes that the “looming presidential election could still cause them some visceral discomfort.” Recalling the 2016 presidential campaign, in which both major candidates’ rhetoric regarding drug pricing caused biotech stocks to plummet, he advises that “investors shouldn’t dismiss the possibility of another election-related selloff” this time. So how can biotech investors survive – or, better yet, take advantage of – this election season? CLICK HERE.
At the beginning of the year, the two biotechs highlighted in today’s article weren’t even big enough to be considered microcap stocks. Now, thanks to their respective COVID-19 vaccine programs, both are fast-growing small-cap stocks with “intriguing twists with their respective COVID-19 vaccine candidates.” So which of these two coronavirus stocks might be the better buy? CLICK HERE.
What’s behind biotech’s recent underperformance? One important factor may be the impending presidential election – and as one exchange-traded fund strategist cited in today’s article explains, “…if history repeats, this pullback may represent an attractive buying opportunity.” What does the history of biotech’s performance leading up to and following presidential elections suggest about buying the biotech dip? CLICK HERE.
When it comes to the advantage that emerging coronavirus stocks have over their more established counterparts, the author of today’s article notes that, “While coronavirus vaccine companies such as Moderna, AstraZeneca, and Pfizer have market caps amounting to tens of billions of dollars, small- to mid-cap coronavirus stocks can potentially be multi-baggers, albeit with higher risks.” He proceeds to take a look at four such emerging coronavirus stocks – and why he believes that “investing $3,000 in any combination of them is a good idea.” CLICK HERE.
“With all of the hype about the race to develop coronavirus vaccines, it’s not surprising that short-sellers have piled on some of the stocks of biotechs with COVID-19 vaccine candidates,” acknowledges the author of today’s article. He further points out, however, that “if these companies have good news, there could be a short-squeeze scenario where the stocks skyrocket as short-sellers scramble to cover their positions.” So which coronavirus vaccine stocks are the most heavily shorted right now, potentially setting up big opportunities for investors? CLICK HERE.
In the wake of two seemingly negative events, shares of the nonalcoholic steatohepatitis (NASH) drug developer focused on in today’s article experienced a sharp sell-off at the end of last week, but one analyst is imploring investors to “view last week’s weakness as a prime buying opportunity” – and sees massive upside potential of 210%. For more on this stock – which boasts a “Strong Buy” consensus rating from analysts – CLICK HERE.
Today’s article highlights three biotech penny stocks to watch right now, including one that the author notes has “had an epic year so far”: It started the year trading under $1 and proceeded to go as high as $5.55 before recently being driven down to as low as $1.68 – and may now be experiencing a turnaround! For more on this particular stock and two more biotech penny stocks to watch right now, CLICK HERE.
A hematology drugmaker that could rise at least 60% and a gene therapy developer that could nearly double top the list of the favorite biotech stocks of a newly-hired analyst at Raymond James. Also making the list of top biotech stocks? A neurology stock, a hematology stock – and more. For a closer look at each of these biotech stocks, CLICK HERE.